Searched for
WOCKHARDT USA
Wockhardt Ltd dumps US generic pharma segment after losses, bets on antibiotics and insulinWockhardt Ltd has decided to shut down its loss-making US generics business to channel its energy and funds into developing new antibiotics...- Wockhardt gets QIDP designation from USFDA for its combination antibioticThe QIDP status is granted to drugs that are effective against a set of multi-drug resistant pathogens identified by the Centre for Disease...
- Wockhardt gets USFDA nod for generic cancer drugWockhardt's Imatinib Mesylate tablets are a generic version of Gleevec, marketed in USA and other countries by Novartis.
- Wockhardt recalls over 1.62 lakh cartons of drugs in USs per the information available on the US Food and Drug Administration's (USFDA) website, Mumbai-based Wockhardt is recalling the drugs for...
- Wockhardt recalls 93K bottles of Captopril tablets from USWockhardt is recalling 93,393 bottles of Captopril tablets, used for treatment of high blood pressure and kidney problems caused by diabete...
- Wockhardt, Cadila and Hospira voluntarily recall drugs in USDrug firms Wockhardt, Cadila Healthcare and Hospira are voluntarily recalling certain lots of drugs in US, according to the US Food and Dru...
- Wockhardt Ltd rallies on receiving QIDP status for two drugsThis is the first instance of an Indian pharmaceutical company receiving a QIDP status, Wockhardt said in a release issued.
- Wockhardt's WCK 771 and WCK 2349 recieve QIDP status from US FDAThis is the first instance of an Indian pharmaceutical company receiving a QIDP status, Wockhardt said in a release issued here.
- USFDA grants Qualified Infectious Disease Product status to two Wockhardt drugsTwo drugs - WCK 771 and WCK 2349 - have received QIDP status, which allows fast-track review of the drug application by the USFDA.
- Wockhardt recalls 8,712 bottles of hypertension drug in US marketWockhardt is recalling over 8,000 bottles of anti-hypertension drug Metoprolol Succinate extended-release tablets following failure of a di...
- Wockhardt Q4 net loss at Rs 191.64 croreDrug firm Wockhardt today reported a consolidated net loss of Rs 191.64 crore for the quarter ended March 31, 2012 burdened by exceptional ...
- Wockhardt gains on Rhinitis drug launchShares of Wockhardt gained over 4% after the pharmaceutical major received final approval from the US FDA for marketing nasal spray of Flut...
- Wockhardt Q2 net at Rs 127.58 croreDrug firm Wockhardt today reported a consolidated net profit of Rs 127.58 crore for the second quarter ended September 30, 2011 on improved...
- Wockhardt June quarter loss narrows to Rs 116 crThe Mumbai-based company had posted a net loss of Rs 189.87 crore in the corresponding quarter of the previous fiscal.
- Wockhardt to launch tablets treating infections in USPharmaceutical firm Wockhardt on Tuesday said it will shortly launch Azithromycin tablets, which are used for treating different kinds of i...
- Wockhardt acquires US-based Morton GrovePharmaceutical major Wockhardt Ltd has acquired Morton Grove Pharmaceuticals, a liquid generic and specialty dermatology company in the US ...
- Wockhardt gets USFDA nod fot CeftriaxoneWockhardt will now be able to market the full range of its potent antibiotic injection, Ceftriaxone, in America as it has received the US F...
- Wockhardt gets US FDA nod to mkt painkillers in USWockhardt Ltd today said it has got US FDA approval to market painkiller tablets containing a combination of Dextropropoxyphene napsylate a...
- Wockhardt gets US nod for Cefotaxime injectionWockhardt Ltd on Thursday said it has received approval from USFDA for marketing antibiotic Cefotaxime sodium injection in the US market.
- Wockhardt gets nod for new drugWockhardt Ltd has received tentative approval from the USFDA for anti-epileptic drug, Divalproex Sodium delayed-release tablets.
Load More
